Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Baird Cuts Price Target on Theravance Biopharma (TBPH) Following 2Q15
August 11, 2015 10:20 AM EDTBaird maintained a Neutral rating on Theravance Biopharma (NASDAQ: TBPH), and cut the price target to $14.00 (from $17.00), following its 2Q15 earnings results. TBPH recorded $7.1M in revenues for the quarter, ahead of consensus 4.25M. $(1.42) in EPS beat consensus estimates of $(1.51).
Analyst Brian Skorney... More
Theravance Biopharma (TBPH) Tops Q2 EPS by 9c
August 10, 2015 4:22 PM EDTTheravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($1.42), $0.09 better than the analyst estimate of ($1.51). Revenue for the quarter came in at $7.1 million versus the consensus estimate of $4.25 million.
Rick E Winningham, Chairman and Chief Executive Officer, commented: "In the first half of 2015, we have focused on executing our strategies to advance TD-4208 to a registrational Phase 3 program, creating an acute care commercial organization in the U.S., while positioning VIBATIV (telavancin) as an important treatment for patients with life-threatening infections, and advancing our two high-value research programs towards the clinic. We are... More
